qingbo wang

Dr. qingbo wang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2021 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
YWYu Wang
Yu Wang
GWGeng Wang
Geng Wang
JBJie Bai
Jie Bai
NZNing Zhao
Ning Zhao
QWqingbo wang
qingbo wang
GWGuobin Wang
Guobin Wang

6 June 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
Birigwa ChristopherBirigwa Christopher
Birigwa Christopher
BQBing Qu
Bing Qu
YTYong-Qing Tong
Yong-Qing Tong
TZTeng Zuo
Teng Zuo
WYWenzheng Yuan
Wenzheng Yuan
QTQiang Tong
Qiang Tong
Background: Detection of colorectal cancer (CRC) currently relies mainly on invasive procedures such as colonoscopy. In experimental models, tumor hypoxia induces epigenetic, metabolic, and immune changes via hypoxia-inducible factor (HIF) signaling. Building on these published insights, this study evaluated whether a panel of biomarkers previously associated with hypoxia-related processes, plasma methylated SEPT9 (mSEPT9), urinary N1, N12-diacetylspermine (DiAcSpm), and systemic inflammatory indices (NLR, PLR, and LMR)—could be combined into a non-invasive diagnostic panel and compared with standard serum tumor markers. This study focused solely on diagnostic performance; it did not directly assess tumor hypoxia or HIF expression in patients. This study was conducted in a clinical diagnostic setting (patients with confirmed CRC, polyps, or benign surgical conditions) and does not represent a population-based screening cohort. Limitations include the lack of an external validation cohort; all analyses were performed on a single dataset, and the reported performance metrics may be optimistic. Independent validation is required before clinical implementation. Methods: This prospective single-center study enrolled 382 participants: 142 with CRC, 62 with colorectal polyps, and 178 non-malignant controls. Plasma mSEPT9 was quantified by real-time PCR, urinary DiAcSpm by ELISA, and inflammatory indices from blood counts. Serum tumor markers (CEA, CA19-9, CA125, and AFP) were measured by immunoassay. Diagnostic accuracy was assessed using ROC analysis and multivariable logistic regression. Results: mSEPT9 (AUC 0.843) and DiAcSpm (AUC 0.831) demonstrated significantly higher diagnostic accuracy than CEA (AUC 0.660) and CA19-9 (AUC 0.649). A combined panel including mSEPT9, DiAcSpm, NLR, PLR, and LMR achieved an AUC of 0.947, with 85.9% sensitivity and 92.9% specificity. This panel also showed strong performance for early-stage CRC (AUC 0.905). Conclusions: A multimarker panel of biomarkers (mSEPT9, DiAcSpm, NLR, PLR, and LMR) provides a non-invasive diagnostic approach for CRC detection in a clinical case–control setting. Validation in asymptomatic screening populations is required before any screening claim can be made. These findings are associative; direct evidence that tumor hypoxia drives these biomarker changes was not obtained and requires future investigation.

30 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Birigwa ChristopherBirigwa Christopher
Birigwa Christopher
BQBing Qu
Bing Qu
YTYong-Qing Tong
Yong-Qing Tong
TZTeng Zuo
Teng Zuo
WYWenzheng Yuan
Wenzheng Yuan
QTQiang Tong
Qiang Tong
Background: Early detection of colorectal cancer (CRC) still relies mainly on invasive screening. Tumor hypoxia induces epigenetic, metabolic, and immune changes via hypoxia-inducible factor (HIF) signaling in experimental models. Building on these insights, this study evaluated whether hypoxia pathway biomarkers—plasma methylated SEPT9 (mSEPT9), urinary N¹, N¹² diacetylspermine (DiAcSpm), and systemic inflammatory indices (NLR, PLR, LMR)—could be combined into a noninvasive diagnostic panel compared with standard serum tumor markers. The study focused solely on diagnostic performance; it did not directly assess tumor hypoxia or HIF expression in patients. Methods: This prospective single-center study enrolled 382 participants: 142 with CRC, 62 with colorectal polyps, and 178 non-malignant controls. Plasma mSEPT9 was quantified by real-time PCR, urinary DiAcSpm by ELISA, and inflammatory indices from blood counts. Serum tumor markers (CEA, CA19-9, CA125, AFP) were measured by immunoassay. Diagnostic accuracy was assessed using ROC analysis and multivariable modeling. Results: mSEPT9 (AUC 0.843) and DiAcSpm (AUC 0.831) demonstrated significantly higher diagnostic accuracy than CEA (AUC 0.660) and CA19-9 (AUC 0.649). A combined panel including mSEPT9, DiAcSpm, NLR, PLR, and LMR achieved an AUC of 0.947, with 85.9% sensitivity and 92.9% specificity. This panel also showed strong performance for early-stage CRC (AUC 0.905).” Conclusions: A multimarker panel of previously reported hypoxia-associated biomarkers (mSEPT9, DiAcSpm, NLR, PLR, and LMR) provides a scalable, noninvasive approach for CRC detection with high diagnostic accuracy. These findings are associative; direct evidence that tumor hypoxia drives these biomarker changes in patients was not obtained and requires future investigation.